127 related articles for article (PubMed ID: 16049514)
1. Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics.
Cerveny CG; Law CL; McCormick RS; Lenox JS; Hamblett KJ; Westendorf LE; Yamane AK; Petroziello JM; Francisco JA; Wahl AF
Leukemia; 2005 Sep; 19(9):1648-55. PubMed ID: 16049514
[TBL] [Abstract][Full Text] [Related]
2. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
Wahl AF; Klussman K; Thompson JD; Chen JH; Francisco LV; Risdon G; Chace DF; Siegall CB; Francisco JA
Cancer Res; 2002 Jul; 62(13):3736-42. PubMed ID: 12097283
[TBL] [Abstract][Full Text] [Related]
3. The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis.
Böll B; Hansen H; Heuck F; Reiners K; Borchmann P; Rothe A; Engert A; Pogge von Strandmann E
Blood; 2005 Sep; 106(5):1839-42. PubMed ID: 15878978
[TBL] [Abstract][Full Text] [Related]
4. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30.
Oflazoglu E; Stone IJ; Gordon KA; Grewal IS; van Rooijen N; Law CL; Gerber HP
Blood; 2007 Dec; 110(13):4370-2. PubMed ID: 17909075
[TBL] [Abstract][Full Text] [Related]
5. Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines.
Heuck F; Ellermann J; Borchmann P; Rothe A; Hansen H; Engert A; von Strandmann EP
J Immunother; 2004; 27(5):347-53. PubMed ID: 15314543
[TBL] [Abstract][Full Text] [Related]
6. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies in vitro and in vivo.
Maeda N; Muta H; Oflazoglu E; Yoshikai Y
Cancer Sci; 2010 Jan; 101(1):224-30. PubMed ID: 19799612
[TBL] [Abstract][Full Text] [Related]
8. Disseminated growth of Hodgkin's-derived cell lines L540 and L540cy in immune-deficient SCID mice.
Kapp U; Düx A; Schell-Frederick E; Banik N; Hummel M; Mücke S; Fonatsch C; Bullerdiek J; Gottstein C; Engert A
Ann Oncol; 1994; 5 Suppl 1():121-6. PubMed ID: 7513537
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
Sekimizu M; Iguchi A; Mori T; Koga Y; Kada A; Saito AM; Horibe K
BMC Cancer; 2018 Feb; 18(1):122. PubMed ID: 29390984
[TBL] [Abstract][Full Text] [Related]
10. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
Hombach A; Jung W; Pohl C; Renner C; Sahin U; Schmits R; Wolf J; Kapp U; Diehl V; Pfreundschuh M
Int J Cancer; 1993 Nov; 55(5):830-6. PubMed ID: 8244580
[TBL] [Abstract][Full Text] [Related]
11. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.
Francisco JA; Cerveny CG; Meyer DL; Mixan BJ; Klussman K; Chace DF; Rejniak SX; Gordon KA; DeBlanc R; Toki BE; Law CL; Doronina SO; Siegall CB; Senter PD; Wahl AF
Blood; 2003 Aug; 102(4):1458-65. PubMed ID: 12714494
[TBL] [Abstract][Full Text] [Related]
12. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30
Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y
Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337
[TBL] [Abstract][Full Text] [Related]
13. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model.
Renner C; Bauer S; Sahin U; Jung W; van Lier R; Jacobs G; Held G; Pfreundschuh M
Blood; 1996 Apr; 87(7):2930-7. PubMed ID: 8639913
[TBL] [Abstract][Full Text] [Related]
14. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma.
Borchmann P; Treml JF; Hansen H; Gottstein C; Schnell R; Staak O; Zhang HF; Davis T; Keler T; Diehl V; Graziano RF; Engert A
Blood; 2003 Nov; 102(10):3737-42. PubMed ID: 12881320
[TBL] [Abstract][Full Text] [Related]
15. SGN-30: a basis for the effective treatment of CD30 positive hematopoietic malignancies.
Pinter-Brown LC
Expert Opin Investig Drugs; 2008 Dec; 17(12):1883-7. PubMed ID: 19012503
[TBL] [Abstract][Full Text] [Related]
16. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.
Law CL; Gordon KA; Collier J; Klussman K; McEarchern JA; Cerveny CG; Mixan BJ; Lee WP; Lin Z; Valdez P; Wahl AF; Grewal IS
Cancer Res; 2005 Sep; 65(18):8331-8. PubMed ID: 16166310
[TBL] [Abstract][Full Text] [Related]
17. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice.
Barth S; Huhn M; Matthey B; Tawadros S; Schnell R; Schinköthe T; Diehl V; Engert A
Blood; 2000 Jun; 95(12):3909-14. PubMed ID: 10845927
[TBL] [Abstract][Full Text] [Related]
18. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells.
Hirsch B; Hummel M; Bentink S; Fouladi F; Spang R; Zollinger R; Stein H; Dürkop H
Am J Pathol; 2008 Feb; 172(2):510-20. PubMed ID: 18187570
[TBL] [Abstract][Full Text] [Related]
19. MDX-060. Medarex.
Hu XF; Xing PX
Curr Opin Investig Drugs; 2005 Dec; 6(12):1266-71. PubMed ID: 16370393
[TBL] [Abstract][Full Text] [Related]
20. Preclinical characterization of SGN-70, a humanized antibody directed against CD70.
McEarchern JA; Smith LM; McDonagh CF; Klussman K; Gordon KA; Morris-Tilden CA; Duniho S; Ryan M; Boursalian TE; Carter PJ; Grewal IS; Law CL
Clin Cancer Res; 2008 Dec; 14(23):7763-72. PubMed ID: 19047103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]